SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-22-000033
Filing Date
2022-10-12
Accepted
2022-10-12 16:21:15
Documents
12
Period of Report
2022-10-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20221006.htm   iXBRL 8-K 41277
  Complete submission text file 0001819790-22-000033.txt   182212

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20221006.xsd EX-101.SCH 1890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20221006_lab.xml EX-101.LAB 24831
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20221006_pre.xml EX-101.PRE 13035
6 EXTRACTED XBRL INSTANCE DOCUMENT tars-20221006_htm.xml XML 11333
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 221307058
SIC: 2836 Biological Products, (No Diagnostic Substances)